SCHEMBL5060093

SCHEMBL5060093

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cn(C(C)(C)C)nc3-c3ccc4ncccc4c3)c(F)c2)ccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 9/20 0.66
BRAF P15056 8/20 0.66
ABL1 P00519 5/20 0.66
MAPK14 Q16539 4/20 0.66
RET P07949 3/20 0.66
KDR P35968 3/20 0.66
MAP3K20 Q9NYL2 3/20 0.66
HIPK4 Q8NE63 3/20 0.66
MET P08581 3/20 0.66
RIPK1 Q13546 2/20 0.66
KIT P10721 2/20 0.66
BCR P11274 2/20 0.66
FGFR1 P11362 2/20 0.66
PDGFRA P16234 2/20 0.66
FLT1 P17948 2/20 0.66
EPHA1 P21709 2/20 0.66
TTK P33981 2/20 0.66
FLT4 P35916 2/20 0.66
FLT3 P36888 2/20 0.66
MAPKAPK2 P49137 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5056363 0.91 RAF1 (0.54) RAF1BRAFABL1MAPK14RET
SCHEMBL5060052 0.90 ABL1 (0.55) RAF1BRAFABL1MAPK14RET
SCHEMBL2025081 0.89 BRAF (0.62) RAF1BRAFABL1MAPK14RET
SCHEMBL5056731 0.88 MAPK14 (0.56) RAF1BRAFABL1MAPK14RET
SCHEMBL5056586 0.88 ABL1 (0.57) RAF1BRAFABL1MAPK14RET
SCHEMBL5054700 0.86 MAPK14 (0.49) RAF1BRAFABL1MAPK14RET
SCHEMBL5056318 0.86 MAPK14 (0.48) RAF1BRAFABL1MAPK14RET
SCHEMBL5054771 0.86 ABL1 (0.55) RAF1BRAFABL1MAPK14RET
SCHEMBL5056415 0.85 ABL1 (0.56) RAF1BRAFABL1MAPK14RET
SCHEMBL5060202 0.85 ABL1 (0.56) RAF1BRAFABL1MAPK14RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 RAF1 55/4885BRAF 2/4885ABL1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.